Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4050784 in advanced solid tumors with SMARCA4 alterations
jRCT2051240129Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of FHD-909 in Non-hematologic malignancy, non-small cell lung cancer (NSCLC) and SMARCA4-deficient undifferentiated carcinoma (SMARCA4-UT) (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Treatment-emergent adverse events, serious adverse events, and adverse events, Maximum tolerated dose / recommended phase 2 dose and 3 more. Started Sep 2024; status: recruiting.
02
Drugs
FHD-909
03
Conditions
Non-hematologic malignancynon-small cell lung cancer (NSCLC)SMARCA4-deficient undifferentiated carcinoma (SMARCA4-UT)
Beyond the preview
Go deeper on jRCT2051240129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240129.